Breaking News Instant updates and real-time market news.

ACOR

Acorda Therapeutics

$23.55

2.5 (11.88%)

07:06
01/08/18
01/08
07:06
01/08/18
07:06

Acorda Therapeutics reports Ampyra ER tablets net sales of $166M for Q4

Acorda Therapeutics reported AMPYRA Extended Release Tablets, 10 mg unaudited net sales for the fourth quarter of 2017 of $166M. Unaudited 2017 full-year net sales were $542M, an increase of approximately 10% from 2016. Final results are subject to completion of the company's year-end audit. "In response to the challenges we faced in 2017, we streamlined Acorda to focus on our most important and valuable initiatives. Based on the Company's proven track record of commercial success in the specialty neurology space, an NDA submitted for a major product and a continued commitment to fiscal responsibility, 2018 will be a transformative year for Acorda," said Ron Cohen, M.D., Acorda's President and CEO. "We are preparing for potential approval and launch of INBRIJA, our investigational inhaled levodopa treatment for symptoms of OFF periods in people with Parkinson's disease taking carbidopa/levodopa. We look forward to working with the FDA during the NDA review process, and to bringing this new treatment option to the PD community to help address an important unmet need. Based on our continued market research we have increased our projection for INBRIJA's US market opportunity to greater than $800M. We are well capitalized through the launch of INBRIJA, and are projecting a 2018 year-end cash balance of over $300M. We are also continuing to prosecute the AMPYRA appeal vigorously in the appellate court. Depending on the outcome of that appeal, we expect to maintain exclusivity of AMPYRA at least through July 2018."

  • 08

    Jan

  • 08

    Jan

ACOR Acorda Therapeutics
$23.55

2.5 (11.88%)

11/16/17
JANY
11/16/17
NO CHANGE
Target $17
JANY
Neutral
Acorda Therapeutics price target cut to $17 from $26 at Janney Capital
Janney Capital analyst Ken Trbovich lowered Acorda Therapeutics' price target to $17 from $26 following the company's announcement regarding adverse events related to Tozadenant. The analyst removed Tozadenant from his model and maintains a Neutral rating on shares.
11/20/17
LEER
11/20/17
NO CHANGE
LEER
Market Perform
Acorda discontinuation of Tozadenant a 'good strategic step,' says Leerink
Leerink analyst Paul Matteis points out that Acorda Therapeutics announced the discontinuation of Tozadenant development in Parkinson's disease in light of a recent safety update last week, noting a significant imbalance in agranulocytosis, sepsis and mortality on drug versus placebo. The analyst notes that he had removed tozadenant from his valuation based on his view that even if the drug had succeeded, these safety issues and related monitoring requirements would be too great of a cost in the context of a moderate symptomatic benefit. The discontinuation of Tozadenant should conserve some cash, he contends, adding that the company's decision is smart as the strategic focus fully shifts to CVT-301, also for Parkinson's Disease. Matteis reiterates a Market Perform rating on the shares.
11/21/17
JANY
11/21/17
NO CHANGE
Target $17
JANY
Neutral
Acorda could be worth $17-$27 in takeover, says Janney Capital
After Acorda Therapeutics announced that it is discontinuing development of tozadenant, an investigational treatment for Parkinson's disease, Janney Capital analyst Ken Trbovich said he believes a sale process appears necessary to protect shareholders from downside that he sees if Acorda remains independent. While the stock may only be worth $10-$11 if Acorda stays independent, it could be worth $17-$27 in a takeout scenario, estimated Trbovich, who maintains a Neutral rating and $17 fair value estimate on Acorda shares.
11/28/17
PIPR
11/28/17
INITIATION
Target $22
PIPR
Neutral
Acorda Therapeutics assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Charles Duncan assumed coverage of Acorda Therapeutics with a Neutral rating and $22 price target. The analyst believes Inbrija could be a best-in-class acute treatment with $800M in peak U.S. sales. He's looking for clinical and regulatory progress "which re-establishes conviction in Acorda's execution."

TODAY'S FREE FLY STORIES

04:55
01/23/18
01/23
04:55
01/23/18
04:55
General news
Breaking General news story  »

Week of 1/19 Redbook to…

04:55
01/23/18
01/23
04:55
01/23/18
04:55
General news
Breaking General news story  »

Chicago Federal Reserve…

FB

Facebook

$185.37

4.08 (2.25%)

, SNAP

Snap

$14.17

0.13 (0.93%)

04:55
01/23/18
01/23
04:55
01/23/18
04:55
Conference/Events
FBN Securities media analysts to hold a group luncheon »

Analysts host a Group…

FB

Facebook

$185.37

4.08 (2.25%)

SNAP

Snap

$14.17

0.13 (0.93%)

TWTR

Twitter

$23.32

-0.34 (-1.44%)

GOOG

Alphabet

$1,155.81

18.3 (1.61%)

GOOGL

Alphabet Class A

$1,164.16

20.66 (1.81%)

LNKD

Acquired by MSFT

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 06

    Feb

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

  • 18

    Mar

04:55
01/23/18
01/23
04:55
01/23/18
04:55
General news
Breaking General news story  »

4-Week Bill Auction to be…

HAWK

Blackhawk

$45.20

-0.05 (-0.11%)

04:48
01/23/18
01/23
04:48
01/23/18
04:48
Downgrade
Blackhawk rating change  »

Blackhawk downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

02:45
01/23/18
01/23
02:45
01/23/18
02:45
General news
FX Update: The dollar gained on the Senate vote »

FX Update: The dollar…

02:25
01/23/18
01/23
02:25
01/23/18
02:25
General news
BoJ's Kuroda sounded dovish at his post-meeting press conference »

BoJ's Kuroda sounded…

CENT

Central Garden & Pet

$37.82

0.09 (0.24%)

20:37
01/22/18
01/22
20:37
01/22/18
20:37
Upgrade
Central Garden & Pet rating change at KeyBanc »

Central Garden & Pet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPAR

Inter Parfums

$45.90

-1.9 (-3.97%)

20:33
01/22/18
01/22
20:33
01/22/18
20:33
Downgrade
Inter Parfums rating change at KeyBanc »

Inter Parfums downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$148.14

0.78 (0.53%)

, PG

Procter & Gamble

$91.89

0.82 (0.90%)

20:25
01/22/18
01/22
20:25
01/22/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

JNJ

Johnson & Johnson

$148.14

0.78 (0.53%)

PG

Procter & Gamble

$91.89

0.82 (0.90%)

VZ

Verizon

$53.46

1.55 (2.99%)

KMB

Kimberly-Clark

$116.91

1.42 (1.23%)

TRV

Travelers

$139.35

1.5 (1.09%)

FITB

Fifth Third

$32.77

0.27 (0.83%)

HBAN

Huntington Bancshares

$16.03

0.22 (1.39%)

WAT

Waters

$214.77

4.05 (1.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 06

    Feb

  • 13

    Feb

  • 16

    Feb

  • 08

    Mar

SSNLF

Samsung

19:26
01/22/18
01/22
19:26
01/22/18
19:26
Hot Stocks
Samsung says new tariff 'great loss' for American consumers, workers »

In reaction to a final…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

FTK

Flotek

$5.71

0.07 (1.24%)

19:23
01/22/18
01/22
19:23
01/22/18
19:23
Hot Stocks
Flotek expands lines of chemistry technologies »

Flotek Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

ACLS

Axcelis

19:22
01/22/18
01/22
19:22
01/22/18
19:22
Upgrade
Axcelis rating change at Stifel »

Axcelis upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

W

Wayfair

$90.64

2.8 (3.19%)

19:22
01/22/18
01/22
19:22
01/22/18
19:22
Downgrade
Wayfair rating change at Stifel »

Wayfair downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

EPE

EP Energy

$2.48

0.17 (7.36%)

19:00
01/22/18
01/22
19:00
01/22/18
19:00
Conference/Events
EP Energy to hold a conference call »

Management discusses its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

BRSS

Global Brass and Copper

$33.30

-0.55 (-1.62%)

18:47
01/22/18
01/22
18:47
01/22/18
18:47
Hot Stocks
Global Brass and Copper reports oil spill at Somers Thin Strip plant »

Somers Thin Strip, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$227.58

7.12 (3.23%)

, DIS

Disney

$111.10

0.51 (0.46%)

18:38
01/22/18
01/22
18:38
01/22/18
18:38
Hot Stocks
Netflix doesn't see Disney-Fox deal as a direct threat »

Says Disney (DIS) and Fox…

NFLX

Netflix

$227.58

7.12 (3.23%)

DIS

Disney

$111.10

0.51 (0.46%)

FOX

21st Century Fox

$36.96

0.7 (1.93%)

FOXA

21st Century Fox

$37.31

0.66 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

T

AT&T

$37.87

0.66 (1.77%)

, TWX

Time Warner

$94.00

0.64 (0.69%)

18:37
01/22/18
01/22
18:37
01/22/18
18:37
Periodicals
Judge orders DOJ to seek consent to give data to AT&T, Time Warner, Reuters says »

Judge Richard Leon, who…

T

AT&T

$37.87

0.66 (1.77%)

TWX

Time Warner

$94.00

0.64 (0.69%)

DIS

Disney

$111.10

0.51 (0.46%)

FOX

21st Century Fox

$36.96

0.7 (1.93%)

FOXA

21st Century Fox

$37.31

0.66 (1.80%)

VIA

Viacom

$39.30

0.1 (0.26%)

VIAB

Viacom

$33.94

0.58 (1.74%)

DISCA

Discovery

$26.33

0.62 (2.41%)

SNI

Scripps Networks

$88.77

0.27 (0.31%)

CMCSA

Comcast

$42.89

0.39 (0.92%)

CMCSK

Comcast

CHTR

Charter

$370.25

4.2 (1.15%)

ATUS

Altice USA

$21.90

0.6 (2.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 12

    Feb

  • 27

    Feb

NFLX

Netflix

$227.58

7.12 (3.23%)

18:25
01/22/18
01/22
18:25
01/22/18
18:25
Hot Stocks
Netflix says it has a ways to go to hit 60M U.S. subscribers »

Says has a ways to go to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

BIVV

Bioverativ

$103.79

39.68 (61.89%)

, SNY

Sanofi

$43.20

-1.4 (-3.14%)

18:15
01/22/18
01/22
18:15
01/22/18
18:15
Downgrade
Bioverativ, Sanofi rating change at Jefferies »

Bioverativ downgraded to…

BIVV

Bioverativ

$103.79

39.68 (61.89%)

SNY

Sanofi

$43.20

-1.4 (-3.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 14

    Feb

  • 16

    Feb

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

ECR

Eclipse Resources

$2.33

0.05 (2.19%)

18:12
01/22/18
01/22
18:12
01/22/18
18:12
Conference/Events
Eclipse Resources to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$227.58

7.12 (3.23%)

18:10
01/22/18
01/22
18:10
01/22/18
18:10
Hot Stocks
Netflix says Asia market projects 'well' »

Says very pleased with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

STLD

Steel Dynamics

$46.57

0.15 (0.32%)

18:06
01/22/18
01/22
18:06
01/22/18
18:06
Hot Stocks
Steel Dynamics CEO says domestic inventory levels moderated »

Steel Dynamics CEO Mark…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

STLD

Steel Dynamics

$46.57

0.15 (0.32%)

18:04
01/22/18
01/22
18:04
01/22/18
18:04
Earnings
Steel Dynamics reports Q4 EPS 54c excluding items, consensus 52c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

IMI

Intermolecular

$1.61

0.14 (9.52%)

18:02
01/22/18
01/22
18:02
01/22/18
18:02
Hot Stocks
Intermolecular and SITRI expand alliance to address Chinese market »

Intermolecular and SITRI…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.